1620474-93-2

Upstream product

• 108-55-4 glutaric anhydride, 
• 1454558-58-7 5-[(2,5-dioxopyrrolidin-1-yl)oxy]-N-[4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl]-5-oxopentanamide 
• 1639843-65-4 2,2’,2”-(10-(4-((2-aminoethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 1380500-86-6 tert-butyl N-{[4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl]methyl}carbamate 
• 1345955-28-3 (4-(6-methyl-1,2,4,5-tetrazin-3- yl)phenyl)methaneamine 
• 15996-76-6 4-cyanobenzylamine hydrochloride 
• 1620474-92-1 4-({[4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl]methyl}carbamoyl)butanoic acid 

Relevant academic research and scientific papers

Development of 68Ga-labelled ultrasound microbubbles for whole-body PET imaging

Microbubble (MB) contrast agents have revolutionalised the way ultrasound (US) imaging can be used clinically and pre-clinically. Contrast-enhanced US offers improvements in soft-tissue contrast, as well as the ability to visualise disease processes at th

A bioorthogonal 68Ga-labelling strategy for rapid in vivo imaging

Herein, we describe a fast and robust method for achieving 68Ga-labelling of the EGFR-selective monoclonal antibody (mAb) Cetuximab using the bioorthogonal Inverse-electron-Demand Diels-Alder (IeDDA) reaction. The in vivo imaging of EGFR is demonstrated, as well as the translation of the method within a two-step pretargeting strategy. This journal is the Partner Organisations 2014.